Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 17, 2023
Discovery & Translation

Improved transgene insertion; plus Synlogic’s autoimmune probiotic and more

BioCentury’s roundup of translational innovations
BioCentury | Jun 18, 2021
Translation in Brief

Blocking POLQ for PARP inhibitor-resistant cancer; plus Innovative Molecules’ herpes simplex therapy

BioCentury’s roundup of translational news
BioCentury | Dec 4, 2020
Deals

Artios deal fourth for synthetic lethality in 2020: Data Byte

Artios and Merck KGaA’s deal marks the fourth time a large company partnered with a synthetic lethality-focused biotech this year, signaling continuing momentum for the tumor-targeting
BioCentury | Jun 17, 2020
Deals

With Ideaya deal, GSK bulks up synthetic lethality side of oncology business

GSK and Ideaya’s deal is the second in a month to move a pharma deeper into synthetic lethality
BioCentury | Sep 4, 2019
Finance

Repare readies for clinic with Cowen-led $82M B round

How Repare's synthetic lethality platform attracted Cowen
BioCentury | Jan 11, 2019
Emerging Company Profile

Artios: Probing DNA Damage

How Artios is attacking a different DNA damage response pathway than PARP
BioCentury | Aug 10, 2018
Financial News

Artios raises £65M series B

BioCentury | Aug 10, 2018
Financial News

Artios raises £65M series B

BioCentury | Jun 23, 2017
Finance

Synthetic vitality

Why Versant, MPM chose Repare as their $68M synthetic lethality play
Items per page:
1 - 10 of 15